TY  - BOOK
AU  - Reem Mahmoud Mohammad Mebed 
AU  - Nahla Shehata Kotb  , 
AU  - Salwa Farouk Sabet , 
TI  - Effect of Wnt/Ý-catenin pathway alteration in hepatocellular carcinoma cell lines and the possible modulation by bevacizumab / 
PY  - 2021///
CY  - Cairo : 
PB  - Reem Mahmoud Mohammad Mebed  , 
KW  - Bevacizumab
KW  - VEGF
KW  - Wnt/Ý-catenin
N1  - Thesis (Ph.D.) - Cairo University - Faculty of Science - Department of Zoology; Issued also as CD
N2  - As about 90% of colorectal cancers and 50% of hepatocellular carcinoma  have activated Wnt/Ý-catenin signaling, the current study aim to examine the  effect of knocking down Ý-catenin on the expression of VEGF-A and Slug as  well as the apoptosis related genes; NF-mB, FasR and c-Flip in HepG2 cells  and the possible alteration of their expression when combined with  Bevacizumab. Expression of VEGF-A and Slug was also studied in Caco-2  cells. It is reported in this study that VEGF-A increases significantly in  response to Bevacizumab alone in HepG2, while VEGF-A and Slug decreased significantly when Bevacizumab was combined with knocked  down Ý-catenin in HepG2. However, Bevacizumab alone is more effective in  reducing the expression of those genes in Caco-2. On the other hand,  Bevacizumab combined with knocked down Ý-catenin remarkably reduced  the level of NF-mB, FasR and c-Flip compared to Bevacizumab only treated  HepG2 cells although the difference was not statistically significant
ER  -